← Leaderboards
Taha Merghoub
Sloan-Kettering Inst Can Research
$4,342,237
Attributed
$9,896,215
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2017–25$2.5M$1.9M$1.3M$625K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,896,215 · 4
By mechanism
R01$9,896,215 · 4
Top collaborators
- Ronald G Blasberg7 shared
- Jason A Koutcher7 shared
- Kayvan R Keshari6 shared
- Vinod P Balachandran4 shared
- Mikala Egeblad1 shared
- Jedd D. Wolchok1 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Michelle S Bradbury$7,087,200
- Ulrich Wiesner$4,616,977
- Timothy An-Thy Chan$21,076,830
- Tobias M Hohl$16,351,909
- Jedd D. Wolchok$10,212,450
Others in their field
Other Emerging Leaders on “Response”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$195,683,539
- Kimberly Smith · Ppd Development Lp$115,671,664
- Paul F Gallagher · Woods Hole Oceanographic Institution$92,619,872
- Kevin Urdahl · Seattle Children'S Hospital$84,741,409
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- Ted Ross · University Of Georgia$70,992,558
Research focus
ResponseCellsTumorImmuneImmunotherapyTumor ImmunityT-LymphocyteIn VitroIn VivoSolid NeoplasmClinically RelevantTumor MicroenvironmentNeoplastic CellImmune Checkpoint BlockadeOverexpressionImageMonitorCharacteristicsClinical TranslationProgrammed Cell Death Protein 1Cell TypeLinkMetabolicCd8b1 Gene
Grant awards (19)
Group 2 Innate Lymphoid Cell Regulation of Pancreatic Cancer Immunity$1,123,263
R01 · FY2025 · CA
Determining the role of neutrophils in anti-tumor immunity and immune-related adverse events in the context of T cell-based therapies$702,748
R01 · FY2025 · CA · contact PI
Image-guided Trp-IDO/TDO-Kyn-AHR pathway inhibition, combined with immunotherapy$461,824
R01 · FY2025 · CA · contact PI
Group 2 Innate Lymphoid Cell Regulation of Pancreatic Cancer Immunity$533,314
R01 · FY2024 · CA
Image-guided Trp-IDO/TDO-Kyn-AHR pathway inhibition, combined with immunotherapy$438,732
R01 · FY2024 · CA · contact PI
Group 2 Innate Lymphoid Cell Regulation of Pancreatic Cancer Immunity$548,714
R01 · FY2023 · CA
Image-guided Trp-IDO/TDO-Kyn-AHR pathway inhibition, combined with immunotherapy$452,588
R01 · FY2023 · CA · contact PI
Group 2 Innate Lymphoid Cell Regulation of Pancreatic Cancer Immunity$623,084
R01 · FY2022 · CA
Image-guided Trp-IDO/TDO-Kyn-AHR pathway inhibition, combined with immunotherapy$324,453
R01 · FY2022 · CA · contact PI
Image-guided Trp-IDO/TDO-Kyn-AHR pathway inhibition, combined with immunotherapy$296,533
R01 · FY2022 · CA · contact PI
Imaging tumor and T cell responses to metabolic and immune modulation therapy$650,075
R01 · FY2021 · CA · contact PI
Image-guided Trp-IDO/TDO-Kyn-AHR pathway inhibition, combined with immunotherapy$633,662
R01 · FY2021 · CA · contact PI
Imaging tumor and T cell responses to metabolic and immune modulation$90,974
R01 · FY2021 · CA · contact PI
Imaging tumor and T cell responses to metabolic and immune modulation therapy$741,049
R01 · FY2020 · CA · contact PI
Imaging tumor and T cell responses to metabolic and immune modulation therapy$718,818
R01 · FY2019 · CA
Imaging tumor and T cell responses to metabolic and immune modulation therapy$712,992
R01 · FY2018 · CA
Imaging tumor and T cell responses to metabolic and immune modulation therapy$70,499
R01 · FY2018 · CA
Imaging tumor and T cell responses to metabolic and immune modulation therapy$712,992
R01 · FY2017 · CA
Imaging tumor and T cell responses to metabolic and immune modulation therapy$59,901
R01 · FY2017 · CA